학술논문
Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study
Original Research
Original Research
Document Type
Report
Author
Source
Diabetes Therapy. February 2022, Vol. 13 Issue 2, p287, 13 p.
Subject
Language
English
ISSN
1869-6953
Abstract
Author(s): Anne Dib [sup.1] , Florence Chartier [sup.1] , Katharina Ihle [sup.2] , Isabelle Jamonneau [sup.1] , Lisa Ludwig [sup.1] , Patrice Darmon [sup.3] Author Affiliations: (1) Eli Lilly France [...]
Introduction The REWIND study demonstrated a cardiovascular (CV) benefit of dulaglutide treatment in patients with type 2 diabetes (T2D) with or without established cardiovascular disease (CVD). The current study aims to describe similarities and differences between characteristics of patients with T2D in France and the REWIND population. Methods A retrospective, observational study was conducted in France using primary care IQVIA electronic medical records. Patients aged [greater than or equal to] 18 years with at least one clinical visit and/or glucose-lowering agent prescription in 2019 were identified. The percentages of patients aged [greater than or equal to] 50 years with established CVD, aged [greater than or equal to] 55 years with subclinical CVD or aged [greater than or equal to] 60 years with multiple CV risk factors based on REWIND definitions were calculated. Results A total of 63,927 patients with T2D were included. Mean age was 67 years, 93% were aged [greater than or equal to] 50 years and 58% were male. The median time since T2D diagnosis was 5.6 years, mean glycated hemoglobin was 7.1% and mean body mass index was 30.4 kg/m.sup.2. Of the patients included in the current study, 59.4% fulfilled REWIND CV criteria; 12.4% of patients were [greater than or equal to] 50 years old with established CVD; 9.7% of patients were aged [greater than or equal to] 55 years with subclinical vascular disease and 44.7% were aged [greater than or equal to] 60 years with [greater than or equal to] 2 CV risk factors. Conclusion Almost 60% of this primary care French cohort with T2D fulfilled key REWIND CV criteria, with a lower percentage of patients having established CVD than REWIND participants.
Introduction The REWIND study demonstrated a cardiovascular (CV) benefit of dulaglutide treatment in patients with type 2 diabetes (T2D) with or without established cardiovascular disease (CVD). The current study aims to describe similarities and differences between characteristics of patients with T2D in France and the REWIND population. Methods A retrospective, observational study was conducted in France using primary care IQVIA electronic medical records. Patients aged [greater than or equal to] 18 years with at least one clinical visit and/or glucose-lowering agent prescription in 2019 were identified. The percentages of patients aged [greater than or equal to] 50 years with established CVD, aged [greater than or equal to] 55 years with subclinical CVD or aged [greater than or equal to] 60 years with multiple CV risk factors based on REWIND definitions were calculated. Results A total of 63,927 patients with T2D were included. Mean age was 67 years, 93% were aged [greater than or equal to] 50 years and 58% were male. The median time since T2D diagnosis was 5.6 years, mean glycated hemoglobin was 7.1% and mean body mass index was 30.4 kg/m.sup.2. Of the patients included in the current study, 59.4% fulfilled REWIND CV criteria; 12.4% of patients were [greater than or equal to] 50 years old with established CVD; 9.7% of patients were aged [greater than or equal to] 55 years with subclinical vascular disease and 44.7% were aged [greater than or equal to] 60 years with [greater than or equal to] 2 CV risk factors. Conclusion Almost 60% of this primary care French cohort with T2D fulfilled key REWIND CV criteria, with a lower percentage of patients having established CVD than REWIND participants.